Tiziana Life Sciences Ltd - Common Shares (TLSA)

♥ 383 Thanks from members

Tiziana Life Sciences Ltd (TLSA) exhibits steady market behavior trading in the $1.24 to $1.47 range, bolstered by significant clinical progress including the completion of dosing for all non-active secondary progressive multiple sclerosis (na-SPMS) participants in the Phase 2a INFORM-MS trial across prominent institutions like Brigham and Women's.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Dr. Gabriele Cerrone Leadership: Dr. Gabriele Cerrone (Executive Chairman) Leadership: Dr. Kunwar Shailubhai (CEO) Holder: Panacea Venture Holder: Institutional Holders Holder: Insiders Foralumab Immunotherapy pipeline Nasal anti-CD3 monoclonal antibody #TLSA #Tiziana Life Sciences #biotech stock #Foralumab #NASDAQ TLSA